Zenas BioPharma, Inc.
ZBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.99B
Close$
$-1.80
106.1% downside
Current Fair Value
106.1% downsideOvervalued by 106.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.99 Billion |
|---|---|
| Enterprise Value | $2.02 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.44 |
| Beta | -1.02 |
| Outstanding Shares | 63,112,314 |
Return
| Return on Equity | -196.03% |
|---|---|
| Return on Assets | -69.03% |
| Return on Invested Capital | -47.37% |
Valuation & Multiples
| P/E Ratio | -3.27 |
|---|---|
| PEG | -2.88 |
| Price to Sales | - |
| Price to Book Ratio | 7.41 |
| Enterprise Value to Revenue | 2015.93 |
| Enterprise Value to EBIT | -6.69 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 0.91 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-1.27
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-1.22
Average shareholder expectationRevenue Estimate
$1.01 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0638▼ 70.41% |
|---|---|
| Total Calls | 296,100▲ 66.35% |
| Total Puts | 18,900▼ 86.17% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.56%▼ 6.33% |
|---|---|
| Total Invested | $1.56B▲ 35.96% |
| Investors Holding | 151▲ 6.00% |
ESG Score
No data
About Zenas BioPharma, Inc.
130 employees
CEO: Mr. Leon Oliver Moulder Jr., M.B.A. Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibod...